FINWIRES · TerminalLIVE
FINWIRES

スティフェル・カナダ、カーゴジェットの第1四半期決算は「堅調」と評価

By

-- スティフェル・カナダによると、カーゴジェット(CJT.TO)はマクロ経済の変動にもかかわらず、堅調な国内ネットワークの業績と中南米における新規チャーター事業の成長に支えられ、第1四半期は好調な業績を報告した。 同社株の買い推奨と目標株価120.00ドルを維持しているアナリストのダリル・ヤング氏は、カーゴジェットの調整後EBITDAが8,190万ドルとなり、市場予想を4.9%上回ったと指摘している。 経営陣は前向きな見通しを示し、国内ネットワークは4月まで好調に推移し、新規チャーター顧客と路線が年間を通じて季節変動を緩和すると見込んでいる。 昨年11月のMD-11型機の運航停止に伴う収益は、今年第3四半期まで継続すると予想されている。国際航空機・乗務員・整備・保険(ACMI)事業は依然として低迷しているものの、南北路線では新たな成長軌道に乗っているようだ(東西路線の回復にはまだ時間がかかるだろう)とヤング氏は付け加えた。 「全体として、CJTは現在の低迷した環境をうまく乗り切っており、関税や貿易摩擦の影響が徐々に薄れるにつれて、業績と株価は上昇するだろうと引き続き考えている。」

Price: $82.17, Change: $+4.47, Percent Change: +5.75%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL